Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3
The experimentally established mechanism targets of Carvedilol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.98 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 3/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
| ▸ | TLR4 | O00206 | 2/20 | 0.98 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | APP | P05067 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carvedilol SCHEMBL4418101 | 1.00 | ADRB2 (0.98) | ADRB2DRD2MAPTTLR4DNM1 | |
| Carvedilol SCHEMBL19712689 | 1.00 | ADRB2 (0.98) | ADRB2DRD2MAPTTLR4DNM1 | |
| Carvedilol SCHEMBL1785549 | 0.99 | ADRB2 (0.96) | ADRB2DRD2MAPTTLR4DNM1 | |
| Carvedilol SCHEMBL1784597 | 0.99 | ADRB2 (0.96) | ADRB2DRD2MAPTTLR4DNM1 | |
| Carvedilol SCHEMBL1172788 | 0.99 | ADRB2 (1.00) | ADRB2DRD2MAPTTLR4DNM1 | |
| Carvedilol SCHEMBL10082334 | 0.99 | ADRB2 (1.00) | ADRB2DRD2MAPTTLR4DNM1 | |
| Carvedilol SCHEMBL29370188 | 0.99 | ADRB2 (1.00) | ADRB2DRD2MAPTTLR4DNM1 | |
| (R)-Carvedilol SCHEMBL232110 | 0.99 | ADRB2 (1.00) | ADRB2DRD2MAPTTLR4DNM1 | |
| (R)-Carvedilol SCHEMBL29382761 | 0.99 | ADRB2 (1.00) | ADRB2DRD2MAPTTLR4DNM1 | |
| Carvedilol SCHEMBL1560204 | 0.99 | ADRB2 (1.00) | ADRB2DRD2MAPTTLR4DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1733727-A | Crystalline carvedilol, processes for the manufacture thereof, pharmaceutical compositions and uses thereof | TEVA PHARMA (IL) | 2006-02-15 | — | — | CN | claimed |
| US-20040225132-A1 | Carvedilol | HILDESHEIM JEAN (IL) | 2004-11-11 | — | — | US | claimed |
| US-20040152757-A1 | Carvedilol | HILDESHEIM JEAN (IL) | 2004-08-05 | — | — | US | claimed |
| EP-1299101-A4 | CARVEDILOL | TEVA PHARMA (IL) | 2004-06-16 | — | — | EP | claimed |
| CN-1449286-A | Carvedilol | TEVA PHARMA (IL) | 2003-10-15 | — | — | CN | claimed |
| EP-1299101-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-04-09 | — | — | EP | claimed |
| US-20020143045-A1 | Carvedilol | TEVA PHARMACEUTICALS USA, INC. | 2002-10-03 | — | — | US | claimed |
| WO-2002000216-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-01-03 | — | — | WO | claimed |
| US-20090326033-A1 | Carvedilol | HILDESHEIM JEAN | 2009-12-31 | — | — | US | disclosed |
| US-7605274-B2 | Carvedilol | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2009-10-20 | — | — | US | disclosed |
| US-7485663-B2 | Carvedilol | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-02-03 | — | — | US | disclosed |
| US-20080194838-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-08-14 | — | — | US | disclosed |
| CN-1308307-C | Pseudopolymorphic forms of carvedilol | HOFFMANN LA ROCHE (CH) | 2007-04-04 | — | — | CN | disclosed |
| US-7126008-B2 | Carvedilol | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-10-24 | — | — | US | disclosed |
| EP-1299101-A4 | CARVEDILOL | TEVA PHARMA (IL) | 2004-06-16 | — | — | EP | disclosed |
| US-6699997-B2 | REACTING 4-(OXIRAN-2-YLMETHOXY)-9H- CARBAZOLE WITH 2-(2-METHOXYPHENOXY)ETHYLAMINE TO PRODUCE CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-03-02 | — | — | US | disclosed |
| CN-1449286-A | Carvedilol | TEVA PHARMA (IL) | 2003-10-15 | — | — | CN | disclosed |
| EP-1299101-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-04-09 | — | — | EP | disclosed |
| US-20020143045-A1 | Carvedilol | TEVA PHARMACEUTICALS USA, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002000216-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194838-A1 | CARVEDILOL | REN, ADRB1, ADRB2 | ADRB2 3/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20090326033-A1 | Carvedilol | REN, ADRB1, ADRB2 | ADRB2 3/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20040152757-A1 | Carvedilol | REN, ADRB1, ADRB2 | ADRB2 3/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20040225132-A1 | Carvedilol | REN, ADRB1, ADRB2 | ADRB2 3/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20020143045-A1 | Carvedilol | REN, ADRB1, ADRB2 | ADRB2 3/4885ADRB1 2/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.